Can branded pharma keep pace as Jan Aushadhi scales up? Kotak flags long-term growth risks

India’s branded pharmaceutical market (IPM) is experiencing strain due to the rapid growth of low-cost alternatives like Jan Aushadhi. While the IPM reported 7.4% growth in April 2025, volume growth remained sluggish due to traction in alternate channels. Kotak Institutional Equities predicts a 10-23% YoY growth in domestic sales for FY26, driven by acute season, […]